CD47 and breast carcinoma: In a study with breast cancer patients, Papadaki [22] demonstrated that CTCs CD47+ can be found in initial, recurrent, and metastatic disease (p = 0.036), being more frequently observed in patients with recurrent and metastatic disease (p = 0.009).